RxDoctor Payments DataLook up a doctor →

Arash Gabayan, MD

Radiation Oncology · Beverly Hills, CANPI 1497867717

Payments from drug & device makers

$260,394in general payments, 2019–2025

Across 615 payments — averaging $423.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$243K
  • Sumitomo Pharma America, Inc.$4K
  • Reflexion Medical, Inc.$2K
  • Bayer$881
  • Daiichi Sankyo Inc.$735
  • AstraZeneca$674
  • plus $9K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Pfizer103$243,102
Sumitomo Pharma America, Inc.5$4,127
Reflexion Medical, Inc.3$1,858
Bayer34$881
Daiichi Sankyo Inc.35$735
AstraZeneca(2 entities)31$674
Johnson & Johnson22$524
Amgen19$484
Genentech USA, Inc.32$484
Novartis26$470
Merck18$356
Puma Biotechnology, Inc.14$352
Pharmacyclics LLC, An Abbvie Company10$336
Heartflow, Inc.8$291
EMD Serono, Inc.11$286
Takeda Pharmaceuticals U.S.A., Inc.18$286
Incyte Corporation12$276
Menarini Silicon Biosystems, Inc.5$270
Gilead8$225
Sun Pharmaceutical Industries Inc.8$214
Stemline Therapeutics Inc.6$210
Telix Pharmaceuticals4$203
AbbVie7$200
E.r. Squibb & Sons, L.L.C.35$198
Siemens Medical Solutions USA, Inc.1$187
Sanofi11$184
Ipsen Biopharmaceuticals, Inc10$181
Regeneron Healthcare Solutions, Inc.10$170
Tersera Therapeutics LLC6$165
Eisai Inc.7$161
Astellas Pharma US Inc9$143
GE HealthCare4$139
Exelixis Inc.4$129
Genmab U.S., Inc.4$128
Teva Pharmaceuticals USA, Inc.7$121
Jazz Pharmaceuticals Inc.5$115
Seagen Inc.5$111
Blueprint Medicines Corporation5$110
Bristol Myers Squibb4$99
AVEO Pharmaceuticals, Inc.4$94
Elekta, Inc.1$76
Tempus AI, Inc1$70
Dendreon Pharmaceuticals LLC2$63
Springworks Therapeutics, Inc.3$62
Acrotech Biopharma Inc.4$60
Morphosys, US Inc.3$58
Lilly USA, LLC2$56
Sanofi-aventis U.S. LLC2$45
Progenics Pharmaceuticals, Inc.2$43
Karyopharm Therapeutics Inc.1$32
Spectrum Pharmaceuticals Inc.1$30
Agios Pharmaceuticals, Inc.1$30
ADC Therapeutics America, Inc.1$30
Novocure Inc.1$30
Invivyd Inc1$28
Amneal Pharmaceuticals LLC1$27
Myriad Genetic Laboratories, Inc.1$26
Fennec Pharmaceuticals, Inc.1$25
Rigel Pharmaceuticals, Inc.1$23
Azurity Pharmaceuticals, Inc.1$23

How this compares

$260,394 in reported general payments places this provider in the 95th percentile of 627 radiation oncology providers in California.

See all radiation oncology providers in California

Medicare billing

Part B allowed, 2024
$1,003,209
Medicare patients
544
Services billed
10,014

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other radiation oncology in Beverly Hills

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →